Strattera Mechanism of Action

Mechanism of Action of Strattera (Atomoxetine)

by

Introduction

Strattera, the brand name for atomoxetine, is a non-stimulant medication used primarily in the treatment of attention-deficit hyperactivity disorder (ADHD). Unlike stimulant medications such as methylphenidate or amphetamines, atomoxetine works through selective modulation of norepinephrine.

Mechanism of Action flowchart
Mechanism of action of Strattera flowchart

Mechanism of Action (Stepwise Points)

  1. Selective Norepinephrine Reuptake Inhibition (NRI)
    Atomoxetine selectively inhibits the norepinephrine transporter (NET), preventing the reuptake of norepinephrine into presynaptic neurons.
  2. Increased Synaptic Norepinephrine
    This results in elevated norepinephrine levels in the prefrontal cortex, an area associated with attention, behavior regulation, and executive function.
  3. Modest Dopaminergic Modulation
    Atomoxetine does not directly affect dopamine reuptake in the striatum but may indirectly enhance dopamine signaling in the prefrontal cortex due to NET inhibition.
  4. Non-Stimulant Profile
    Because it does not affect dopamine significantly in reward pathways, it has minimal abuse potential and lacks typical stimulant-associated side effects.
Strattera Mechanism of Action
Mechanism of action of Strattera
Strattera Mechanism of Action
Mechanism of action of Strattera

Pharmacokinetics

  • Absorption: Well absorbed orally; peak plasma levels in 1–2 hours.
  • Bioavailability: ~63%; affected by first-pass metabolism.
  • Metabolism: Primarily metabolized by CYP2D6; extensive polymorphic variability.
  • Half-life: ~5.2 hours in extensive metabolizers; up to 21 hours in poor metabolizers.
  • Excretion: Primarily renal.

Clinical Uses

  • Attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults
  • May be considered in patients with risk of substance abuse or stimulant intolerance

Adverse Effects

  • Gastrointestinal disturbances (nausea, decreased appetite)
  • Insomnia or somnolence
  • Increased heart rate and blood pressure
  • Mood swings or irritability
  • Sexual dysfunction (especially in adults)
  • Rare: Suicidal ideation (boxed warning)

Comparative Analysis

FeatureAtomoxetine (Strattera)MethylphenidateAmphetamine
Drug ClassNRIDopamine/norepinephrine reuptake inhibitorDopamine/norepinephrine releaser
Abuse PotentialLowModerateHigh
Onset of ActionDelayed (1–2 weeks)Rapid (1 hour)Rapid (30–60 min)
Duration24 hours4–12 hours6–12 hours
Primary NeurotransmitterNorepinephrineDopamine & NorepinephrineDopamine & Norepinephrine

Explanation: Atomoxetine is preferred in patients with a history of substance abuse or in those requiring 24-hour symptom control without stimulant-related side effects.

Multiple Choice Questions (MCQs)

  1. What is the primary mechanism of action of atomoxetine?
    a) Dopamine release
    b) Norepinephrine reuptake inhibition
    c) Serotonin agonism
    d) GABA-A modulation
  2. Strattera is classified as a:
    a) Stimulant
    b) Non-stimulant
    c) SSRI
    d) MAOI
  3. Which enzyme is primarily involved in atomoxetine metabolism?
    a) CYP3A4
    b) CYP2D6
    c) CYP2C9
    d) CYP1A2
  4. Strattera’s abuse potential is:
    a) High
    b) Low
    c) Moderate
    d) Comparable to methylphenidate
  5. Common cardiovascular effect of atomoxetine:
    a) Bradycardia
    b) Increased heart rate
    c) Hypotension
    d) QT prolongation
  6. Atomoxetine has the most significant effect in which brain region?
    a) Striatum
    b) Hippocampus
    c) Prefrontal cortex
    d) Cerebellum
  7. One advantage of atomoxetine over stimulants is:
    a) Stronger efficacy
    b) No abuse potential
    c) Immediate effect
    d) Less expensive
  8. Atomoxetine is especially preferred in patients with:
    a) Depression
    b) Obesity
    c) Substance abuse risk
    d) Schizophrenia
  9. Atomoxetine onset of therapeutic action is typically:
    a) Within 30 minutes
    b) 1–2 weeks
    c) 24 hours
    d) 6–8 weeks
  10. Atomoxetine may cause sexual dysfunction due to:
    a) Dopaminergic excess
    b) Norepinephrine modulation
    c) Serotonin blockade
    d) GABA activation

FAQs

Q1: Is atomoxetine a first-line treatment for ADHD?
A1: Yes, especially in patients who cannot tolerate or are at risk with stimulant use.

Q2: Can atomoxetine be used in adults?
A2: Yes, it is approved for ADHD in both children and adults.

Q3: Does it require titration?
A3: Yes, gradual dose escalation helps minimize side effects.

Q4: Is a drug holiday recommended?
A4: Not typically, since it requires continuous administration for efficacy.

References

Leave a Comment